IP Library › Granted Patent US 9,708,353

Granted Patent B2

US 9,708,353 · App. 14/620,700 · Granted Jul 18, 2017

Heterobicyclic sphingosine 1-phosphate analogs

View Patent ↗

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US 9,708,353
App. No.: 14/620,700
Granted: Jul 18, 2017
Kind: B2

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

Compounds that have agonist activity at one or more of the S1P receptors are provided. The compounds are sphingosine analogs that, after phosphorylation, can behave as agonists at S1P receptors.

Claims (153)

1. A compound of formula (I):

or a pharmaceutically acceptable salt thereof, wherein:

A 1 is —C(X 1 )═;

A 2 is —C(X 2 )═;

A 3 is —C(X 3 )(X 3′ )—;

A 4 is C(X 4 )(X 4′ )—;

A 5 is C(X 5 )(X 5′ )—;

A 6 is —C(X 6 )═;

X 1 is hydrogen, halo, hydroxy, nitro, cyano, alkyl, haloalkyl, cycloalkyl, halocycloalkyl, alkoxy, haloalkoxy, cycloalkoxy, halocycloalkoxy, acyl, aminoacyl, —NR f R g , —N(R f )SO 2 R g , —SO 2 R f , —SO 2 NR f R g , —CO 2 R f , trialkylamino, aryl, or heteroaryl;

X 2 is hydrogen, halo, hydroxy, nitro, cyano, alkyl, haloalkyl, cycloalkyl, halocycloalkyl, alkoxy, haloalkoxy, cycloalkoxy, halocycloalkoxy, acyl, aminoacyl, —NR f R g , —N(R f )SO 2 R g , —SO 2 R f , —SO 2 NR f R g , —CO 2 R f , trialkylamino, aryl, or heteroaryl;

X 3 is hydrogen, halo, hydroxy, nitro, cyano, alkyl, haloalkyl, cycloalkyl, halocycloalkyl, alkoxy, haloalkoxy, cycloalkoxy, halocycloalkoxy, acyl, aminoacyl, —NR f R g , —N(R f )SO 2 R g , —SO 2 R f , —SO 2 NR f R g , —CO 2 R f , trialkylamino, aryl, or heteroaryl;

X 3′ is hydrogen, halo, hydroxy, nitro, cyano, alkyl, haloalkyl, cycloalkyl, halocycloalkyl, alkoxy, haloalkoxy, cycloalkoxy, halocycloalkoxy, acyl, aminoacyl, —NR f R g , —N(R f )SO 2 R g , —SO 2 R f , —SO 2 NR f R g , —CO 2 R f , trialkylamino, aryl, or heteroaryl;

X 4 is hydrogen, halo, hydroxy, nitro, cyano, alkyl, haloalkyl, cycloalkyl, halocycloalkyl, alkoxy, haloalkoxy, cycloalkoxy, halocycloalkoxy, acyl, aminoacyl, —NR f R g , —N(R f )SO 2 R g , —SO 2 R f , —SO 2 NR f R g , —CO 2 R f , trialkylamino, aryl, or heteroaryl;

X 4′ is hydrogen, halo, hydroxy, nitro, cyano, alkyl, haloalkyl, cycloalkyl, halocycloalkyl, alkoxy, haloalkoxy, cycloalkoxy, halocycloalkoxy, acyl, aminoacyl, —NR f R g , —N(R f )SO 2 R g , —SO 2 R f , —SO 2 NR f R g , —CO 2 R f , trialkylamino, aryl, or heteroaryl;

X 5 is hydrogen, halo, hydroxy, nitro, cyano, alkyl, haloalkyl, cycloalkyl, halocycloalkyl, alkoxy, haloalkoxy, cycloalkoxy, halocycloalkoxy, acyl, aminoacyl, —NR f R g , —N(R f )SO 2 R g , —SO 2 R f , —SO 2 NR f R g , —CO 2 R f , trialkylamino, aryl, or heteroaryl;

X 5′ is hydrogen, halo, hydroxy, nitro, cyano, alkyl, haloalkyl, cycloalkyl, halocycloalkyl, alkoxy, haloalkoxy, cycloalkoxy, halocycloalkoxy, acyl, aminoacyl, —NR f R g , —N(R f )SO 2 R g , —SO 2 R f , —SO 2 NR f R g , —CO 2 R f , trialkylamino, aryl, or heteroaryl;

X 6 is hydrogen, halo, hydroxy, nitro, cyano, alkyl, haloalkyl, cycloalkyl, halocycloalkyl, alkoxy, haloalkoxy, cycloalkoxy, halocycloalkoxy, acyl, aminoacyl, —NR f R g , —N(R f )SO 2 R g , —SO 2 R f , —SO 2 NR f R g , —CO 2 R f , trialkylamino, aryl, or heteroaryl;

Y is —OR f , —(CR f R g )OR f , —(CR f R g ) 2 OR f , —O—P(O)(OR f )OR g , —OC(O)R c , —C(O)OR c , —(CR f R g )—P(O)(OR f )OR g , —(C(OH)R f )—P(O)(OR f )OR g , —S—P(O)(OR f )OR g , tetrazole, —SO 2 NHR f , —SO 3 , —CONHR f , —Si(OH) 2 , or —B(OH) 2 ;

W is —CR f R g —, —NR f —, —O—, —S—, —SO—, or —SO 2 —;

Cy is cycloalkyl, cycloalkenyl, heterocyclyl, aryl, or heteroaryl; wherein Cy is optionally substituted by 1-6 substituents selected from the group consisting of hydrogen, halo, hydroxy, nitro, cyano, —NR f R g , alkyl, haloalkyl, cycloalkyl, cycloalkenyl, cycloalkylalkyl, cycloalkenylalkyl, heterocyclylalkyl, arylalkyl, heteroarylalkyl, alkoxy, haloalkoxy, cycloalkylalkoxy, cycloalkenylalkoxy, heterocyclylalkoxy, aryloxy, arylalkoxy, heteroaryloxy, heteroarylalkoxy, acyl, cycloalkylacyl, cycloalkenylacyl, heterocyclylacyl, arylacyl, heteroarylacyl, thioalkyl, alkenyl, alkynyl, cycloalkenyl, heterocyclyl, aryl, and heteroaryl;

L 1 is —CH 2 —, —CHF—, or —CF 2 —;

Z 4 is hydrogen, halo, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, or —OR f ;

or Z 4 is —CH 2 — bound to the carbon atom to which Y is bound;

or L 1 , Z 4 , Y, and the atoms to which they are bound form a 4-7 membered cycloalkyl group or a 4-7 membered heterocyclyl group having 1 or 2 heteroatoms selected from O and N;

R a is hydrogen, alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl, or heterocyclyl; wherein each of alkyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl and heterocycle are optionally substituted with 1 to 5 substituents independently selected from the group consisting of halo, oxo, —CN, —CHO, —CF 3 , —OH, —NO 2 , alkyl, —OCF 3 , alkoxy, cycloalkoxy, cycloalkenoxy, amino, alkylamino, dialkylamino, acylamino, aminoacyl, alkylsulfonyl, alkylaminosulfonyl, and dialkylaminosulfonyl;

R b is hydrogen, alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl, or heterocyclyl; wherein each of alkyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl and heterocycle are optionally substituted with 1 to 5 substituents independently selected from the group consisting of halo, oxo, —CN, —CHO, —CF 3 , —OH, —NO 2 , alkyl, —OCF 3 , alkoxy, cycloalkoxy, cycloalkenoxy, amino, alkylamino, dialkylamino, acylamino, aminoacyl, alkylsulfonyl, alkylaminosulfonyl, and dialkylaminosulfonyl;

or R b and Z 4 are taken to together to form —C(O)O— or ═C(R f )O—;

R c is alkyl, aryl, trifluoromethyl, methylsulfonyl, trifluoromethylsulfonyl, p-tolylsulfonyl, or a group selected such that —OCOR c is a good leaving group;

each R f , independently, is hydrogen, alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl, or heterocyclyl; wherein each of alkyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl and heterocycle are optionally substituted with 1 to 5 substituents independently selected from the group consisting of halo, oxo, —CN, —CHO, —CF 3 , —OH, —NO 2 , alkyl, —OCF 3 , alkoxy, cycloalkoxy, cycloalkenoxy, amino, alkylamino, dialkylamino, acylamino, aminoacyl, alkylsulfonyl, alkylaminosulfonyl, and dialkylaminosulfonyl;

each R g , independently, is hydrogen, alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl, or heterocyclyl; wherein each of alkyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl and heterocycle are optionally substituted with 1 to 5 substituents independently selected from the group consisting of halo, oxo, —CN, —CHO, —CF 3 , —OH, —NO 2 , alkyl, —OCF 3 , alkoxy, cycloalkoxy, cycloalkenoxy, amino, alkylamino, dialkylamino, acylamino, aminoacyl, alkylsulfonyl, alkylaminosulfonyl, and dialkylaminosulfonyl;

wherein the aryl is a monocyclic, bicyclic, or tricyclic carbocyclic ring system having one or two aromatic rings; the heteroaryl is an optionally substituted mono- or bicyclic cyclic ring system containing one, two, or three heteroatoms, wherein the heteroatoms are independently selected from oxygen, sulfur, and nitrogen; and the heterocyclyl is an optionally substituted mono- or bicyclic carbocyclic ring system containing one, two, three, or four heteroatoms, wherein the heteroatoms are independently selected from oxygen, sulfur, and nitrogen.

2. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein W is —O—.

3. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R a and R b , independently, are each H or alkyl.

4. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein Y is —OR f .

5. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein Y is —OH or —O—P(O)(OR f )OR g .

6. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein X 6 is H, halo, alkyl, cycloalkyl, or haloalkyl.

7. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein A 3 is —C(X 3 )H—, A 4 is —C(X 4 )H—, and A 5 is —C(X 5 )H—.

8. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein Cy has the formula:

wherein

Z 1 is a bond, —[C(R d R e )] x —, —CR d ═CR e —, —O—, —NR f —;

Z 2 is a bond, —[C(R d R e )] y —, —CR d ═CR e —, —O—, —NR f —;

Z 3 is a bond, —[C(R d R e )] z —, —CR d ═CR e —, —O—, —NR f —;

each of x, y, and z, independently, is 1 to 3;

each R d , independently, is H, halo, hydroxy, alkyl, haloalkyl, alkenyl, alkoxy, cycloalkyl, —C(O)NR f R g , —NR f R g , —NR f C(O)R g , or —SO 2 NR f R g ;

each R e , independently, is H, halo, hydroxy, alkyl, haloalkyl, alkenyl, alkoxy, or cycloalkyl, —C(O)NR f R g , —NR f R g , —NR f C(O)R g , or —SO 2 NR f R g ;

R 1a and R 1b , independently, are hydrogen, halo, hydroxy, nitro, cyano, —NR f R g , alkyl, haloalkyl, cycloalkyl, cycloalkenyl, cycloalkylalkyl, cycloalkenylalkyl, heterocyclylalkyl, arylalkyl, heteroarylalkyl, alkoxy, cycloalkylalkoxy, cycloalkenylalkoxy, heterocyclylalkoxy, arylalkoxy, heteroarylalkoxy, acyl, cycloalkylacyl, cycloalkenylacyl, heterocyclylacyl, arylacyl, heteroarylacyl, thioalkyl, alkenyl, alkynyl, cycloalkenyl, heterocyclyl, aryl, or heteroaryl;

or R 1a and R 1b , when taken together, are C 2 -C 5 alkylene optionally terminated by or interrupted by 1 or 2 oxygen atoms, or C 2 -C 5 alkenylene optionally terminated by or interrupted by 1 or 2 oxygen atoms;

R 2a and R 2b , independently, are hydrogen, halo, hydroxy, nitro, cyano, —NR f R g , alkyl, haloalkyl, cycloalkyl, cycloalkenyl, cycloalkylalkyl, cycloalkenylalkyl, heterocyclylalkyl, arylalkyl, heteroarylalkyl, alkoxy, cycloalkylalkoxy, cycloalkenylalkoxy, heterocyclylalkoxy, arylalkoxy, heteroarylalkoxy, acyl, cycloalkylacyl, cycloalkenylacyl, heterocyclylacyl, arylacyl, heteroarylacyl, thioalkyl, alkenyl, alkynyl, cycloalkenyl, heterocyclyl, aryl, or heteroaryl;

or R 1a and R 2a , when taken together, are C 1 -C 5 alkylene optionally terminated by or interrupted by 1 or 2 oxygen atoms, or C 2 -C 5 alkenylene optionally terminated by or interrupted by 1 or 2 oxygen atoms;

wherein R 1a , R 1b , R 2a , and R 2b are each, independently, substituted with 0-5 substituents selected from halo, hydroxy, nitro, cyano, —NR f R g , or —CO 2 R f .

9. The compound of claim 8 , or a pharmaceutically acceptable salt thereof, wherein R 1a and R 2a are both hydrogen.

10. The compound of claim 8 , or a pharmaceutically acceptable salt thereof, wherein Z 1 is —CH 2 CH 2 —.

11. The compound of claim 10 , or a pharmaceutically acceptable salt thereof, wherein Z 2 is —CH 2 —.

12. The compound of claim 11 , or a pharmaceutically acceptable salt thereof, wherein Z 3 is a bond.

13. The compound of claim 8 , or a pharmaceutically acceptable salt thereof, wherein R 1b is fluoro, chloro, bromo, iodo, methyl, difluoromethyl, triflurormethyl, ethyl, 1,1-difluoroethyl, propyl, isopropyl, n-butyl, i-butyl, t-butyl, n-pentyl, isopentyl, 1,1-dimethylpropyl, neopentyl, cyclopentyl, n-hexyl, cyclohexyl, methoxy, trifluoromethoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, i-butoxy, t-butoxy, n-pentyloxy, i-pentyloxy, 1,1-dimethylpropoxy, neopentyloxy, cyclopentyloxy, n-hexyloxy, or cyclohexyloxy.

14. A compound of formula (II):

or a pharmaceutically acceptable salt thereof, wherein:

Y is —OR f , —(CR f R g )OR f , —(CR f R g ) 2 OR f , —O—P(O)(OR f )OR g , —OC(O)OR c , —C(O)OR c , —(CR f R g )—P(O)(OR f )OR g , —(C(OH)R f )—P(O)(OR f )OR g , —S—P(O)(OR f )OR g , tetrazole, —SO 2 NHR f , —SO 3 , —CONHR f , —Si(OH) 2 , or —B(OH) 2 ;

Z 4 is hydrogen, halo, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, or —OR f ;

or Z 4 is —CH 2 — bound to the carbon atom to which Y is bound;

or Z 4 , Y, and the atoms to which they are bound form a 4-7 membered cycloalkyl group or a 4-7 membered heterocyclyl group having 1 or 2 heteroatoms selected from 0 and N;

R c is alkyl, aryl, trifluoromethyl, methylsulfonyl, trifluoromethylsulfonyl, p-tolylsulfonyl, or a group selected such that —OCOR c is a good leaving group;

Z 1 is a bond, —[C(R d R e )] x , or —CR d ═CR e —;

Z 2 is a bond, —[C(R d R e )] x , or —CR d ═CR e —;

each of x and y, independently is 1 to 3;

each R d , independently, is H, halo, hydroxyl, alkyl, alkenyl, alkoxy, or cycloalkyl;

each R e , independently, is H, halo, hydroxyl, alkyl, alkenyl, alkoxy, or cycloalkyl;

15. The compound of claim 14 , wherein Y is —OR f .

16. The compound of claim 15 , wherein Y is —OH or —O—P(O)(OR f )OR g .

17. The compound of claim 14 , wherein X 6 is H, halo, alkyl, cycloalkyl, or haloalkyl.

18. The compound of claim 14 , wherein Z 1 is —CH 2 CH 2 —.

19. The compound of claim 18 , wherein Z 2 is —CH 2 CH 2 —.

20. The compound of claim 19 , wherein R 1a is hydrogen, halo, hydroxy, alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, arylalkyl, alkoxy, cycloalkylalkoxy, arylalkoxy, or aryl.

21. The compound of claim 14 , wherein Y is —OH or —O—P(O)(OR f )OR g ; Z 4 is H or —OH; X 1 , X 2 , X 3 , X 4 , and X 5 are each H; X 3′ , X 4′ , and X 5′ are each H; and X 6 is H, halo, alkyl, cycloalkyl, or haloalkyl.

22. The compound of claim 14 , wherein Z 1 is —(CH 2 ) x — and Z 2 is —(CH 2 ) y —.

23. The compound of claim 22 , wherein R 1a is alkyl, haloalkyl, cycloalkyl, aryl, or arylalkoxy.

24. The compound of claim 14 , having the formula:

or a pharmaceutically acceptable salt thereof.

25. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of formula (I):

or a pharmaceutically acceptable salt thereof, wherein:

A 1 is —C(X 1 )═;

A 2 is —C(X 2 )═;

A 3 is —C(X 3 )(X 3′ )—;

A 4 is C(X 4 )(X 4′ )—;

A 5 is C(X 5 )(X 5′ )—;

A 6 is —C(X 6 )═;

W is —CR f R g —, —NR f —, —O—, —S—, —SO—, or —SO 2 —;

L 1 is —CH 2 —, —CHF—, or —CF 2 —;

Z 4 is hydrogen, halo, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, or —OR f ;

or Z 4 is —CH 2 — bound to the carbon atom to which Y is bound;

or L 1 , Z 4 , Y, and the atoms to which they are bound form a 4-7 membered cycloalkyl group or a 4-7 membered heterocyclyl group having 1 or 2 heteroatoms selected from 0 and N;

or R b and Z 4 are taken to together to form —C(O)O— or ═C(R f )O—;

R c is alkyl, aryl, trifluoromethyl, methylsulfonyl, trifluoromethylsulfonyl, p-tolylsulfonyl, or a group selected such that —OCOR c is a good leaving group;

wherein the aryl is a monocyclic, bicyclic, or tricyclic carbocyclic ring system having one or two aromatic rings; the heteroaryl is a mono- or bicyclic cyclic ring system containing one, two, or three heteroatoms, wherein the heteroatoms are independently selected from oxygen, sulfur, and nitrogen; and the heterocyclyl is a mono- or bicyclic carbocyclic ring system containing one, two, three, or four heteroatoms, wherein the heteroatoms are independently selected from oxygen, sulfur, and nitrogen.

26. The pharmaceutical composition of claim 25 , wherein Y is —OH or —O—P(O)(OR f )OR g .

27. The pharmaceutical composition of claim 25 , wherein the compound is represented by formula (II):

or a pharmaceutically acceptable salt thereof, wherein:

Z 4 is hydrogen, halo, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, or —OR f ;

or Z 4 is —CH 2 — bound to the carbon atom to which Y is bound;

or Z 4 , Y, and the atoms to which they are bound form a 4-7 membered cycloalkyl group or a 4-7 membered heterocyclyl group having 1 or 2 heteroatoms selected from 0 and N;

R c is alkyl, aryl, trifluoromethyl, methylsulfonyl, trifluoromethylsulfonyl, p-tolylsulfonyl, or a group selected such that —OCOR c is a good leaving group;

Z 1 is a bond, —[C(R d R e )] x , or —CR d ═CR e —;

Z 2 is a bond, —[C(R d R e )] x , or —CR d ═CR e —;

each of x and y, independently is 1 to 3;

each R d , independently, is H, halo, hydroxyl, alkyl, alkenyl, alkoxy, or cycloalkyl;

each R e , independently, is H, halo, hydroxyl, alkyl, alkenyl, alkoxy, or cycloalkyl;

28. The pharmaceutical composition of claim 27 , wherein Y is —OH or —O—P(O)(OR f )OR g .

29. The pharmaceutical composition of claim 27 , wherein the compound is represented by the following formula:

or a pharmaceutically acceptable salt thereof.

Assignments (2)

CHANGE OF NAME Recorded May 4, 2015

From: BIOGEN IDEC MA INC.

To: BIOGEN MA INC.

Reel/Frame 035571/0926 →

ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 11, 2015

From: GUCKIAN, KEVIN M.; CALDWELL, RICHARD D.; KUMARAVEL, GNANASAMBANDAM; LEE, WEN-CHERNG; LIN, EDWARD YIN-SHIANG; LIU, XIAOGAO; MA, BIN; SCOTT, DANIEL M.; SHI, ZHAN; ZHENG, GUO ZHU; TAVERAS, ARTHUR G.; THOMAS, JERMAINE

To: BIOGEN IDEC MA, INC.

Reel/Frame 035387/0895 →